esk981
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 8, 2018 (NCT03456804)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Fibroblast growth factor receptor 1INHIBITOR
FGFR1 inhibitor
- Tyrosine-protein kinase TIE-2INHIBITOR
TEK inhibitor
FLT1 inhibitor
KDR inhibitor
FLT4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05988918 | Phase 2 | Jan 31, 2024 | University of Michigan |
| NCT03562507 | Phase 2 | Aug 31, 2018 | Department of Veteran Affairs, University of Michigan |
| NCT03456804 | Phase 2 | Mar 8, 2018 | National Cancer Institute (NCI), Wayne State University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Michigan | Academic/Hospital | 2 | 2 | 1 | 2018 |
| Department of Veteran Affairs | Government | 1 | 0 | 1 | 2018 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2018 |
| Wayne State University | Academic/Hospital | 1 | 1 | 1 | 2018 |
4 organizations
Page 1 / 1